CLAIMS

1. Use of a composition comprising mesenchymal precursor cells (MPCs) or mesenchymal stem cells (MSCs) comprising a KIF11 siRNA or a vector for expressing a KIF11 shRNA in the manufacture of a medicament for delivery of the KIF11 siRNA or shRNA to cancer target cells.

2. Use according to Claim 1, in which the KIF11 siRNA or KIF11 shRNA comprises the nucleic acid sequence as shown in any one of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8 or 9.

3. Use according to any preceding claim, in which the composition comprises MPCs.

4. Use according to any preceding claim, in which the target cancer cell is from a pancreatic cancer or a colorectal cancer.

5. Use according to any preceding claim, in which the KIF 11 siRNA or shRNA kills a target cancer cell to which the siRNA or shRNA is transferred, but does not substantially affect viability of MPC from which the siRNA or shRNA is transferred.

6. Use according to any preceding claim, in which the MPCs express STRO-1.

7. Use according to any preceding claim, in which when the MPCs are contacted with a target cell, the MPCs form a gap junction with the target cancer cell, whereby the KIF11 siRNA or shRNA is delivered to the target cancer cell by traversing the gap junction.

8. Use according to Claim 7, in which the target cancer cell does not express connexin 43.

9. Use according to Claim 8, in which the target cancer cell viability is a white blood cell.

10. Use according to Claim 9, in which the mesenchymal lineage precursor or stem cells express a connexin that is also expressed by a target cancer cell in the subject's cancer.

11. Use according to any preceding claim, in which the target cancer cell is a syncytial cancer cell.

12. Use according to any preceding claim, in which the MPCs or MSC were transfected with a KIF11 siRNA at a concentration from at least 100 nM to about 500 nM.

13. Use according to Claim 12, in which the MLPSCs were modified by transfection of the inhibitory oligonucleotide at a concentration of at least 200 nM.

14. Use according to Claim 12, in which the MLPSCs were modified by transfection of the inhibitory oligonucleotide at a concentration of about 500 nM.